New York, December 21, 2023 – Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company’s innovative StemSpine® treatment known as AlloStem™ (CELZ-201-DDT). Timothy Warbington, CEO of Creative Medical Technology, said, “The FDA’s clearance and IRB approval allowing us to pursue this clinical trial is another milestone event for … Continue reading Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial